由于2026年2月18日的股份升至5.92美元,内部人士出售了99K美元固体生物科学股份。 Insiders sold $99K in Solid Biosciences stock as shares rose to $5.92 on Feb. 18, 2026.

2026年2月18日 包括CFO Kevin Tan、COO David T. Howton和主管Jessie Hanrahan在内的若干实心生物科学内幕人士共出售17 007股股票,平均价格为5.82美元,共计约98 991美元。 On February 18, 2026, several Solid Biosciences insiders, including CFO Kevin Tan, COO David T. Howton, and executive Jessie Hanrahan, sold a combined total of 17,007 shares at an average price of $5.82, totaling approximately $98,991. 这些交易在证交会申报中披露,将其所有权股份减少5.16%至6.64%。 The transactions, disclosed in SEC filings, reduced their ownership stakes by 5.16% to 6.64%. 该公司的股票在当天上涨到5.92美元,交易量超过平均数量,市场上限为4.6123亿美元。 The company’s stock rose to $5.92 on the day, trading above its average volume, with a market cap of $461.23 million. 尽管P/E比率为负数,分析师仍维持“机动购买”共识评级,平均价格目标为14.70美元。 Despite a negative P/E ratio, analysts maintain a "Moderate Buy" consensus rating with a $14.70 average price target. 固体生物科学正在开发SGT-001,这是利用AAV矢量对杜尚氏肌肉萎缩进行的一项微营养素基因疗法。 Solid Biosciences is developing SGT-001, a micro-dystrophin gene therapy for Duchenne muscular dystrophy, using an AAV vector.